We are thrilled to be named “a firm to watch” by The Guardian. Undoubtedly, the success of our MASH studies this past year and the cutting-edge clinical trials we have planned for next year solidified our name on this list.
To read more, click here
We are thrilled to be named “a firm to watch” by The Guardian. Undoubtedly, the success of our MASH studies this past year and the cutting-edge clinical trials we have planned for next year solidified our name on this list.
To read more, click here